Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment.

The inducement grants consisted of (1) non-qualified stock options to purchase 275,061 shares of Intellia’s common stock with an exercise price of $11.26 per share (the “option award”), the closing price of Intellia’s common stock as reported by Nasdaq Global Market on October 26, 2026, with one-third of the options underlying the option award vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter until fully vested on the third anniversary of the grant date and (2) time-based restricted stock units (“RSUs”) for 199,822 shares of Intellia’s common stock (the “RSU award”), with one-third of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date.